Clinical trials: Not Condition-specific
Peripheral T Cell Lymphoma, PTCL
Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms
This was a multi-center, prospective, non-randomized, open-label, Phase 2 clinical study to evaluate the safety and efficacy of BGB-A317 in participants with relapsed or refractory mature T- and natural killer (NK)-cell…
- Conditions
- Peripheral T Cell Lymphoma, PTCL, Extranodal NK/T-cell Lymphoma, Extranodal NK/T-cell Lymphoma, Nasal Type
- Trial name
- NCT03493451
- Testing
- Tislelizumab
- Where
- 24 sites in Canada, China and 3 more
- Volunteers
- 77 people
- Sponsor
- BeiGene
Relapsed or Refractory Lymphoma Including ENKL
A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma
This study is a multi-center, global, open-label, Phase 1b/2 clinical study, and it will be conducted at multiple study sites in several countries, including Japan, Korea, and Singapore, to reveal the safety, tolerability, dose…
- Trial name
- NCT06761677
- Testing
- Brincidofovir
- Where
- 8 sites in China, Japan and 1 more
- Volunteers
- 43 people
- Sponsor
- SymBio Pharmaceuticals
Not Condition-specific
Promoting Flu Vaccination Through a Mobile Wellness Program
The investigators design a 6-week messaging campaign aimed at promoting flu vaccination among fully insured members of a national payer that participate in a wellness program offered by the insurer through a mobile app.
- Trial name
- NCT02908893
- Testing
- In-app and push notification mobile messages
- Where
- United States
- Volunteers
- 50,286 people, healthy volunteers welcome
- Sponsor
- Evidation Health
Schizophrenia, Schizoaffective Disorder
Schizophrenic Patients Taking Part in Integrated Care Program
Purpose of this non-interventional study (NIS) is to assess the effect of the participation in an integrated care program on treatment outcomes in patients treated with Seroquel for schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreni-form Disorder, Delusional Disorder
- Trial name
- CARE I (NCT00617214)
- Where
- 14 sites in Germany
- Volunteers
- 20 people
- Sponsor
- AstraZeneca
Multiple Myeloma (MM), Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies
The main aims of this 2-part study are: Phase I: To determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of IDP-121 in patients with multiple myeloma (MM), diffuse large B cell lymphoma not otherwise…
- Conditions
- Multiple Myeloma (MM), Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double Hit Lymphoma, High Grade B-Cell Lymphoma, Not Otherwise Specified
- Trial name
- CASSANDRA (NCT05908409)
- Testing
- IDP-121
- Where
- 11 sites in Spain
- Volunteers
- 37 people
- Sponsor
- IDP Discovery Pharma S.L.
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High-grade B-cell Lymphoma
P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies
Phase 1 study comprised of open-label, dose escalation and expansion cohort study of P-CD19CD20-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed/refractory B cell malignancies
- Conditions
- Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High-grade B-cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), Transformed Follicular Lymphoma (tFL)
- Trial name
- NCT06014762
- Testing
- P-CD19CD20-ALLO1, Rimiducid
- Where
- 16 sites in United States
- Volunteers
- 120 people
- Sponsor
- Poseida Therapeutics, Inc.
Autistic Disorder, Autism
Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine
The purpose of this randomized withdrawal study is to evaluate the safety, tolerability, and efficacy of memantine compared with placebo in pediatric patients with autism, Asperger's Disorder, or Pervasive Developmental Disorder…
- Conditions
- Autistic Disorder, Autism, Asperger's Disorder, Asperger Syndrome
- Trial name
- NCT01592747
- Testing
- Memantine Hydrochloride (HCl)
- Where
- 94 sites in United States, Belgium and 13 more
- Volunteers
- 479 people
- Sponsor
- Forest Laboratories
T Cell Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified
Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1 Positive T Cell Lymphoma
The purpose of this study is to test the safety and efficacy of AUTO4 a chimeric antigen receptor (CAR) T cell treatment targeting TRBC1 in patients with relapsed or refractory TRBC1 positive selected T-Non-Hodgkin Lymphoma (NHL).
- Conditions
- T Cell Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Anaplastic Large Cell Lymphoma
- Trial name
- NCT03590574
- Testing
- AUTO4
- Where
- 5 sites in Spain, United Kingdom
- Volunteers
- 20 people
- Sponsor
- Autolus Limited
Autism Spectrum Disorder (ASD), Autism
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
The purpose of this study is to evaluate the safety and tolerability of memantine in pediatric (6-12 years old) patients with autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) and…
- Conditions
- Autism Spectrum Disorder (ASD), Autism, Autistic Disorder, Asperger's Disorder
- Trial name
- NCT01592786
- Testing
- Memantine Hydrochloride (HCl)
- Where
- 118 sites in United States, Australia and 16 more
- Volunteers
- 906 people
- Sponsor
- Forest Laboratories
Post Concussive Syndrome, Chronic, Post Concussion Symptoms
Accelerated Transcranial Magnetic Stimulation Intervention for Post-Concussion Syndrome
This study looks at the effects of accelerated intermittent theta burst stimulation (aiTBS) on patients with chronic and acute post-concussion syndrome.
- Conditions
- Post Concussive Syndrome, Chronic, Post Concussion Symptoms, Post Concussive Syndrome, Post Concussion Syndrome
- Trial name
- NCT07211919
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Cognitive FX
Autism Spectrum Disorder (ASD), Autism
Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
The objective of this study is to evaluate the long-term safety and tolerability of memantine in the treatment of pediatric patients with autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified…
- Conditions
- Autism Spectrum Disorder (ASD), Autism, Autistic Disorder, Asperger's Disorder
- Trial name
- NCT01592773
- Testing
- Memantine Hydrochloride (HCl)
- Where
- 106 sites in United States, Belgium and 14 more
- Volunteers
- 747 people
- Sponsor
- Forest Laboratories
B Cell Lymphoma, NHL, Adult
SynKIR-310 for Relapsed/Refractory B-NHL
This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administered to participants with relapsed/refractory B-NHL.
- Conditions
- B Cell Lymphoma, NHL, Adult, Mantle Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma
- Trial name
- NCT06544265
- Testing
- SynKIR-310
- Where
- 5 sites in United States
- Volunteers
- 36 people
- Sponsor
- Verismo Therapeutics
Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
This Phase II trial evaluates the optimization of the cytokine release syndrome (CRS) profile for glofitamab in combination with gemcitabine and oxaliplatin (Glofit-GemOx) followed by glofitamab monotherapy treatment regimen (Cohort…
- Trial name
- NCT06806033
- Testing
- Obinutuzumab, Glofitamab, Gemcitabine
- Where
- 53 sites in United States, Australia and 5 more
- Volunteers
- 130 people
- Sponsor
- Hoffmann-La Roche
Conduct Disorder, Disruptive Behavior Disorder
A Study of the Safety and Effectiveness of Risperidone Versus Placebo for the Treatment of Conduct Disorder in Children With Mild, Moderate, or Borderline Mental Retardation
The purpose of the study is to assess the effectiveness and safety of an oral solution of risperidone (an antipsychotic medication) versus placebo in the treatment of conduct disorder in children with mild, moderate, or…
- Conditions
- Conduct Disorder, Disruptive Behavior Disorder, Oppositional Defiant Disorder
- Trial name
- NCT00266552
- Testing
- risperidone
- Volunteers
- 118 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Depressive Disorder, Depressive Disorder, Major Depressive Disorder
Detection Algorithm for Recurrence or Relapse of Depression Thanks to a Smartwach
Globally, 3.8% of the population, or approximately 280 million people, suffer from depression. In France, 12.5% of adults experienced a major depressive episode (MDE) in 2021, with women being twice as affected as men.
- Conditions
- Depressive Disorder, Depressive Disorder, Major Depressive Disorder, Depressive Disorder Not Otherwise Specified (NOS)
- Trial name
- DALIA (NCT06789822)
- Testing
- Invitation to wear the smartwatch
- Where
- France
- Volunteers
- 800 people
- Sponsor
- Dalia Care
Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Expanded Access Program for Epcoritamab
The purpose of this program is to provide investigational epcoritamab, an antibody also known as GEN3013 (DuoBody-CD3xCD20), in an expanded access setting for eligible patients with relapsed and/or refractory (R/R) large B-cell…
- Conditions
- Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Primary Mediastinal Large B-cell Lymphoma (PMBCL), High Grade B-cell Lymphoma (HGBCL)
- Trial name
- NCT05733650
- Testing
- Epcoritamab
- Sponsor
- Genmab
Bronchial Asthma (Only the Patients With Severe or Intractable Bronchial Asthma Which Could Not be Controlled With the Existing Therapy)
TEZSPIRE (Tezepelumab) Asthma Japan Post-Marketing Study (PMS)
The purpose of the investigation is to confirm the followings under the post-marketing actual long-term use of Tezspire. 1. Development of related AEs 2.
- Trial name
- NCT05729711
- Where
- 33 sites in Japan
- Volunteers
- 416 people
- Sponsor
- AstraZeneca
Conduct Disorder, Oppositional Defiant Disorder
A Study of the Safety and Effectiveness of Risperidone for the Treatment of Conduct Disorder and Other Disruptive Behavior Disorders in Children Ages 5 to 12 With Mild, Moderate, or Borderline Mental Retardation
The purpose of the study is to assess the safety and effectiveness of oral risperidone (an antipsychotic medication) in the treatment of conduct disorder and other disruptive behavior disorders in children ages 5 to 12 with mild…
- Conditions
- Conduct Disorder, Oppositional Defiant Disorder, Disruptive Behavior Disorder
- Trial name
- NCT00250354
- Testing
- Risperidone oral solution
- Volunteers
- 110 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Autism Spectrum Disorders
Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders
This is an open-label extension protocol that will provide necessary data on the safety, tolerability, pharmacokinetics and efficacy of STX209 among subjects with ASD.
- Trial name
- NCT01706523
- Testing
- STX209 (arbaclofen)
- Where
- 25 sites in United States
- Volunteers
- 165 people
- Sponsor
- Seaside Therapeutics, Inc.
Relapsed or Refractory T-cell Lymphomas
A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)
The purpose of this study is to test the safety, tolerability, efficacy, and drug levels of BMS-986369 (Golcadomide) in participants with relapsed or refractory T-cell lymphomas in Japan (GOLSEEK-3).
- Trial name
- NCT06035497
- Testing
- BMS-986369
- Where
- 40 sites in Japan
- Volunteers
- 83 people
- Sponsor
- Bristol-Myers Squibb